MITF-related melanoma and renal cell carcinoma predisposition syndrome Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

8 events

Apr 2024A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Zhejiang University — PHASE1

TrialNOT YET RECRUITING

Apr 2024A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Merck Sharp & Dohme LLC — PHASE2

TrialACTIVE NOT RECRUITING

Mar 2022Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

UNICANCER — PHASE3

TrialRECRUITING

Dec 2020A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Daiichi Sankyo — PHASE1

TrialACTIVE NOT RECRUITING

Sep 2020

GAVRETO®: FDA approved

treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test

FDAcompleted

Jun 2019Biomarkers of Renal Cancer

Biorek S.R.L.

TrialRECRUITING

Sep 2017Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis — PHASE1

TrialACTIVE NOT RECRUITING

Dec 1990Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

National Cancer Institute (NCI)

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

GAVRETOï¿½

Rigel Pharmaceuticals, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

GAVRETOï¿½

(pralsetinib)Orphan drug

Rigel Pharmaceuticals, Inc.

Kinase Inhibitor [EPC]

12.1 Mechanism of Action Pralsetinib is a kinase inhibitor of wild-type RET and oncogenic RET fusions (CCDC6- RET ) and mutations ( RET V804L, RET V80...

Approved Sep 2020FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

6 active trials

1Phase 3

1Phase 2

2Phase 1

2Unknown

6Total recruiting

Search clinical trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome →

Recent News & Research

No recent news articles indexed yet for MITF-related melanoma and renal cell carcinoma predisposition syndrome.
Search PubMed for MITF-related melanoma and renal cell carcinoma predisposition syndrome →

Browse all MITF-related melanoma and renal cell carcinoma predisposition syndrome news →

Specialist Network

No specialists currently listed for MITF-related melanoma and renal cell carcinoma predisposition syndrome.

View all MITF-related melanoma and renal cell carcinoma predisposition syndrome specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰